Joint venture, Hologen Neuro AI, will expedite Phase 3 development of AAV-GAD for Parkinson’s Disease and industrialize ...

With MeiraGTx eyeing up how to take the drug through phase 3 and onto commercialization, Hologen has stepped in. The ...

The venture aims to advance MeiraGTx’s Parkinson’s gene therapy through Phase III trials with up to $430m in funding from ...

In addition to the $200 million payment, Hologen will provide up to $230 million in committed funding to support the development of AAV-GAD for Parkinson's disease through commercialization.

MeiraGTx and Hologen form a neuro-AI drug development joint venture, with up to $430M in funding to advance Parkinson's and CNS treatments.

Investing.com -- Shares of MeiraGTx Holdings plc ( Nasdaq: NASDAQ: MGTX) climbed 13% following the announcement of a strategic collaboration with Hologen AI, aimed at accelerating the Phase 3 ...

In comes, DeepSeek, a Chinese AI startup that has shown it is possible to develop AI models without spending much. It ...

The Parkinson’s gene therapy, AAV-GAD, delivers the glutamic acid decarboxylase (GAD) gene into the subthalamic nucleus, a part of the brain key to motor control. It’s the same region targeted ...

Today announced strategic collaboration with Hologen AI, including a $200 million upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million in ...

Hologen has committed up to $430m in funding to support the development and commercialisation of AAV-GAD, MeiraGTx’s investigational gene therapy for Parkinson’s disease. The AI company will ...

MeiraGTx (MGTX) stock gains as the company teams up with Hologen to form a JV to advance gene therapies for Parkinson's and other CNS diseases. Read more here.